US FDA approves first COVID-19 treatment for young children
LOS ANGELES, April 26 (Bernama) -- The US Food and Drug Administration (FDA) on Monday expanded its approval of the COVID-19 treatment Veklury, also known as remdesivir, to include pediatric patients 28 days of age and older weighing at least 3 kilogrammes who are infected by SARS-CoV-2.
This action makes Veklury the first approved COVID-19 treatment for children less than 12 years of age, said the FDA.
Veklury is approved for young children who are hospitalised, or have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, according to the FDA, said Xinhua.
Previously Veklury was only approved to treat COVID-19 for certain adults and pediatric patients 12 years of age and older who weigh at least 40 kg.
"As COVID-19 can cause severe illness in children, some of whom do not currently have a vaccination option, there continues to be a need for safe and effective COVID-19 treatment options for this population," said Patrizia Cavazzoni, director of the FDA's Centre for Drug Evaluation and Research.
-- BERNAMA
BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 IFLIX channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.
Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial
